Episode of 28/10/2019
When we think of globalization, we imagine tennis shoes made in Thailand and smartphones made in Korea. But even the medicines we take every day are produced in distant factories and often without stringent controls. So you can offer patients low prices and make a good profit margin as well. But by dint of cost cutting, in some cases the drug can come out contaminated with impurities.
As with numerous batches of Valsartan, a medicine against high blood pressure, which the European drug authorities, including the Italian Aifa, have withdrawn in recent months because they contain nitrosamines, that is, potentially carcinogenic agents. The medicine was produced by a Chinese company, Zhejiang Huahai, which, in order to produce faster, has placed a harmful product on the market for years. Report will take a trip back from a tablet to see what's behind its production chain, between environmental pollution, the proliferation of antibiotic-resistant bacteria and the exploitation of human guinea pigs for clinical trials.